Rank Name of Executive Company Base Salary ($000) Bonus ($000) Total ($000) 1 Lewis H. Bender Emisphere Technologies Inc. 306 75 381 2 Robert G. Johnson Kosan Biosciences Inc. 265 100 365 3 Donald R. Marvin Orchid Biosciences Inc. 302 62 364 4 Robert S. Whitehead (31) ZymoGenetics Inc. (a) 306 41 347 5 John J. Wulf InterMune Inc. 235 88 323 6 W. Richard Staub Pharmaceutical Product Development Inc. 156 165 321 7 Robert L. Kirkman Protein Design Labs

Rank Name of Executive Company Potential Realizable Value of Option Grants # ($000) No. of Securities Underlying Options (000) % of Total Options Granted To Employees (%) Excercise or Base Price ($/Share) ### Stock Price 12/31/02 ($) 1 Peter D. Meldrum (1) Myriad Genetics Inc.** 787,125 35 4.7 35.76 14.6 2 Arthur J. Higgins (2) Enzon Pharma. Inc.** 21,594 800 57.08 28.17-57.67 16.72 3 David M. Mott MedImmune Inc. 19,532 750 12.57 41.41 27.17 4 Paul N. Clark ICOS

Rank Name of Executive Age Company FYE Value of Exercisable In-the-Money Options ($000) Total No. of Shares Owned By CEO # (000) Percent of Co. Stock Owned By CEO ## (%) Stock Price 12/31/01 ($) Stock Price 12/31/02 ($) Percent Change Stock Price (%) 1 William H. Rastetter 54 IDEC Pharmaceuticals Corp. 56,078 2,770,830 1.8 68.93 33.17 -51.9 2 John C. Martin 51 Gilead Sciences Inc. 38,049 1,908,434 1 32.86 34 3.5 3 W. Scott Harkonen 51 InterMune Inc. 29,325 612

Name of Executive Company Base Salary ($000) Bonus ($000) Other # ($000) Long-Term Compensation ## ($000) Total Direct Compensation ($000) Kevin W. Sharer (1) Amgen Inc. 980 1,800 514 9,821 13,115 William H. Rastetter IDEC Pharmaceuticals Corp. 575 384 3 10,783 11,745 John C. Martin Gilead Sciences Inc. 653 616 0 4,520 5,789 Thomas E. D'Ambra (2) Albany Molecular Research Inc. 250 0 5,119 0 5,369 Frank Baldino, Jr. (3) Cephalon Inc. 800 2,409 109 1,735 5

Rank Name of Executive Company Bonus ($000) Base Salary ($000) Bonus As a Percent of Base Salary (%) Other ($000) Stock Price 12/31/01 ($) Stock Price 12/31/02 ($) Percent Change Stock Price (%) 1 Frank Baldino, Jr. (1) Cephalon Inc. 2,409 800 301.13 109 75.585 48.66 -35.6 2 Kevin W. Sharer (2) Amgen Inc. 1,800 980 183.67 514 56.44 48.34 -14.4 3 Sean P. Lance (3) Chiron Corp. 1,250 777 160.88 136 43.84 37.6 -14.2 4 David M. Mott MedImmune Inc. 1,200

Rank Name of Executive Company Base Salary ($000) Base Salary Prior FY ($000) Percent Change Base Salary (%) Stock Price 12/31/01 ($) Stock Price 12/31/01 ($) Percent Change Stock Price (%) Cum. Total Return on Investment # ($) Approx. Mkt. Cap. 12/31/02 ## ($M) 1 Henri A. Termeer (1) Genzyme Corp. 1,162 1,038 11.9 59.86 29.57 -50.6 N/A 6,499.70 2 Kevin W. Sharer Amgen Inc. 980 933 5 56.44 48.34 -14.4 357.24 62,894.20 3 David M. Mott MedImmune Inc. 833 725

For Legal Officers Who Received A Full Year Of Salary, 67 Companies

For Business And Corporate Development Executives Who Received A Full Year Of Salary, 42 Companies

For R&D Executives Who Received A Full Year Of Salary, 130 Companies

For CFOs Who Received A Full Year Of Salary, 143 Companies

(For CEOs Who Received A Full Year Of Salary, 202 Companies)

(For CEOs Who Received A Full Year Of Salary, 202 Companies)

(For CEOs Who Received A Full Year Of Salary, 202 Companies)

For CEOs Who Received A Full Year Of Salary, 202 Companies

For CEOs Who Received A Full Year of Salary, 202 Companies

The BioWorld Executive Compensation Report 2003 Table Of Contents I. Introduction Introduction To BioWorld s 2003 Report on CEO Compensation in the Biotechnology Industry II. Chief Executive Officer Compensation CEOs ranked by annual compensation (base salary plus bonus) Median annual CEO compensation Median CEO compensation package (total direct compensation) Top 25 CEOs ranked by base salary only Top 25 CEOs ranked by bonus only Median and quartile information for CEO compensation

Definitions & methodology Using the same 225 proxy statements, we have gathered data on the compensation of executives responsible for legal affairs in the industry. The sample size of companies shrinks to 78 in the case of this position because many companies have no such position listed among the top wage earners (companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000). In addition, a number

Definitions & methodology Using the same 225 proxy statements, we have gathered data on the compensation of executives responsible for business and/or corporate development in the industry. The sample size of companies shrinks to 54 in the case of this position because many companies have no such position listed among the top wage earners (companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives who earn more than $100,000